press releases

 
Opened the crowdfunding campaign of AROMICS for a new cancer treatment

January 2017

El periódico de Catalunya

Opened the crowdfunding campaign of AROMICS for a new cancer treatment

The goal of the campaign launched by AROMICS, located at the Barcelona Science Park, is completing regulatory preclinical package of the first-in-human clinical studies of its drug NAX035 for the treatment of malignant mesothelioma, an aggressive, poor prognosis and highly treatment-resistant asbestos-associated malignancy, directly linked to asbestos exposure.

 
Aromics launches a crowdfunding campaing for its mesothelioma drug

December 2016

El periodico

Aromics launches a crowdfunding campaing for its mesothelioma drug

Aromics launches an "equity crodfunding" or collaborative financial campaign to capture 300.000 euros. The campaign is devoted to small private investors that want to participate in the project. The operation is made thru Capital Cell -a platfom accredited by Generalitat de Catalunya- specialized in Crowdfunding for biotech companies. the goal is to complete preclinical package of NAX035, a novel drug for the treatment of malignant mesothelioma, an agressive cancer realted to asbestos exposure.

 
Aromics, a development stage biopharmaceutical company

September 2015

La Vanguardia

Aromics, a development stage biopharmaceutical company

AROMICS, founded in 2005, is a development stage biopharmaceutical company working on the development of novel antitumor and antiviral agents.

 
AROMICS participa en el programa "Passa els estius al Parc"

August 2015

AROMICS participa en el programa "Passa els estius al Parc"

AROMICS acull un estudiant en pràctiques dins la 14 edició del programa "Passa els estius al Parc", impulsat pel Parc Científic de Barcelona.

 
Nuevos tratamientos para enfermedades minoritarias

August 2015

La Vanguardia

Nuevos tratamientos para enfermedades minoritarias

The biotechnology companies are working on rare diseases' market. In particular AROMICS focuses on the development of a novel therapy for malignant mesothelioma, a rare tumor frequently related to work exposure to asbestos.